Management of Heart Failure in the Hospitalized Patient. Ronald Witteles, M.D. Stanford University School of Medicine October 27, 2012

Size: px
Start display at page:

Download "Management of Heart Failure in the Hospitalized Patient. Ronald Witteles, M.D. Stanford University School of Medicine October 27, 2012"

Transcription

1 Management of Heart Failure in the Hospitalized Patient Ronald Witteles, M.D. Stanford University School of Medicine October 27, 2012

2 I have nothing to disclose Disclosures

3 What is Heart Failure? Not as simple as it may sound What does it mean?

4 What is Heart Failure? Not as simple as it may sound What does it mean? Edema

5 What is Heart Failure? Not as simple as it may sound What does it mean? Edema Low cardiac output

6 What is Heart Failure? Not as simple as it may sound What does it mean? Edema Low cardiac output Lack of end-organ perfusion

7 What is Heart Failure? Not as simple as it may sound What does it mean? Edema Low cardiac output Lack of end-organ perfusion Something else???

8 An Interrogatory What are my PA catheterization numbers? RA: RV: PA: PCWP: CO: CI:

9 An Interrogatory What are my PA catheterization numbers? RA: 3 mmhg RV: 18/3 mmhg PA: 18/7/11 mmhg PCWP: 7 mmhg CO: 5.2 L/min CI: 2.8 L/min/m 2

10 An Interrogatory What are my PA catheterization numbers? RA: 3 mmhg RV: 18/3 mmhg PA: 18/7/11 mmhg PCWP: 7 mmhg CO: 5.2 L/min CI: 2.8 L/min/m 2 So what are the PA catheteriztion numbers on my heart failure clinic outpatient with dilated cardiomyopathy and a 35% LVEF?

11 The Answer My clinic patient s catheterization numbers RA: RV: PA: PCWP: CO: CI:

12 The Answer My clinic patient s catheterization numbers RA: 9 mmhg RV: PA: PCWP: CO: CI:

13 The Answer My clinic patient s catheterization numbers RA: 9 mmhg RV: 35/9 mmhg PA: PCWP: CO: CI:

14 The Answer My clinic patient s catheterization numbers RA: 9 mmhg RV: 35/9 mmhg PA: 35/15/22 mmhg PCWP: CO: CI:

15 The Answer My clinic patient s catheterization numbers RA: 9 mmhg RV: 35/9 mmhg PA: 35/15/22 mmhg PCWP: 14 mmhg CO: CI:

16 The Answer My clinic patient s catheterization numbers RA: 9 mmhg RV: 35/9 mmhg PA: 35/15/22 mmhg PCWP: 14 mmhg CO: 5.0 L/min CI: 2.7 L/min

17 The Answer My clinic patient s catheterization numbers RA: 9 mmhg RV: 35/9 mmhg PA: 35/15/22 mmhg PCWP: 14 mmhg CO: 5.0 L/min CI: 2.7 L/min So His resting cardiac output is preserved, But at the expense of higher filling pressures

18 A Definition We Can Agree On? Heart failure is a syndrome characterized by: The need for elevated filling pressures to maintain an acceptable cardiac output. Inability to achieve an adequate cardiac output for organ perfusion in response to a stressor (e.g. exercise, infection, surgery)

19 A Problem of Semantics Three different patients with 3 unique pathophysiologic problems three different treatments! The term heart failure exacerbation (or acute decompensated heart failure ) leads to incorrect treatment much of the time.

20 Admission 1 68 y.o. African-American man with ischemic cardiomyopathy. Baseline echo: Moderate LV dilatation, LVEF 25-35%, 1+ MR. Comes to ER for worsening LE edema Baseline meds: Carvedilol 25 mg bid, lisinopril 20 mg bid, ASA 325 mg qd, furosemide 40 mg bid, digoxin mg qd.

21 Admission 1 PE: Wt 90 kg (up from 85 kg 1 month ago) BP 115/65, HR 65, SaO2 94% RA, scant bibasilar crackles, no significant murmurs/gallops, 3+ LE edema. Labs: Na 137, K 4.1, Cr 1.3 (baseline 1.4), BNP 1100, troponin I <0.1. CXR: Cardiomegaly, mild pulmonary edema ECG: Sinus rhythm at 65 bpm, old LBBB

22 What Do You Do? What about the carvedilol? 1) Continue 25 mg po bid 2) Cut to 12.5 mg po bid 3) Stop for now with plans to reinitiate at mg bid 4) Stop for now with plans to reinitiate at 25 mg bid

23 What Do You Do? What about the carvedilol? 1) Continue 25 mg po bid 2) Cut to 12.5 mg po bid 3) Stop for now with plans to reinitiate at mg bid 4) Stop for now with plans to reinitiate at 25 mg bid

24 What about the digoxin? What Do You Do? 1) Stop digoxin (no mortality benefit anyway) 2) Continue digoxin at mg qd 3) Increase to 0.25 mg qd 4) Check a digoxin level & adjust dose accordingly

25 What about the digoxin? What Do You Do? 1) Stop digoxin (no mortality benefit anyway) 2) Continue digoxin at mg qd 3) Increase to 0.25 mg qd 4) Check a digoxin level & adjust dose accordingly

26 Question 1: What is the Problem? In this patient, the problem is volume overload Nothing actually happened acutely Are heart failure exacerbation or acute decompensated heart failure really the best terms? Biggest risk to the patient iatrogenesis. First, do no harm.

27 A Potential Complication Patient gets aggressive diuresis & is feeling better, but then develops 15 second run of VT Electrolyte panel shows K 3.1 Potassium is repleted, but patient still has runs of NSVT Team decides to start patient on amiodarone to suppress VT (a separate talk ) Putting the issue of whether or not to start amiodarone aside is there anything else that needs to be done upon amiodarone initiation?

28 A Potential Complication Patient gets aggressive diuresis & is feeling better, but then develops 15 second run of VT Electrolyte panel shows K 3.1 Potassium is repleted, but patient still has runs of NSVT Team decides to start patient on amiodarone to suppress VT (a separate talk ) Putting the issue of whether or not to start amiodarone aside is there anything else that needs to be done upon amiodarone initiation? Halve the digoxin dose!

29 How to Manage this Patient 1) Loop diuretics, paying attention to electrolytes Goal is to get patient back to dry weight Sending out too early only means he will be back soon! 2) Continue carvedilol/digoxin at present doses 3) Determine why the patient developed volume overload (sodium intake, medication noncompliance/confusion, underdosed diuretics) 4) Make sure patient has appropriate close outpatient follow-up (ideally in HF clinic) 5) Consider additional therapies that may help him long-term

30 Potential Long-Term Therapies 1) Medical therapies Aldosterone antagonist with close electrolyte f/u Hydralazine/nitrates 2) Device therapy If EF is chronically this low ICD indicated Given LBBB & Class III sx, biventricular pacing indicated 3) Statin?

31 Potential Long-Term Therapies 1) Medical therapies Aldosterone antagonist with close electrolyte f/u Hydralazine/nitrates 2) Device therapy If EF is chronically this low ICD indicated Given LBBB & Class III sx, biventricular pacing indicated 3) Statin?

32 How About Sodium/Fluid Intake?

33 How About Sodium/Fluid Intake? Problem is too much sodium, not too much water! Do not waste time/energy on fluid restricting unless patient is hyponatremic Patient s non-restricted water intake is based on maintaining sodium concentration if he takes in less salt, he will take in less water. Best advice (in normonatremic patient): Drink to quench thirst not more, not less.

34 How About Sodium/Fluid Intake? Low sodium diet is critical Most patients think low fat/sugar diet is most important for them. Multiple techniques to do low sodium Best diet fresh meat/fruits/vegetables Nothing prepackaged/nothing that anyone has had the opportunity to add salt to.

35 Trial of Free-Fluid vs. Fluid-Restriction in Treatment of Patients Admitted with ADHF * Time to clinical stability = symptomatic improvement with no evidence of fluid overload, stable weight x 48h, off IV therapies x 48h, no change in cardiac medications for 48h. Adapted from Travers et al. J Card Fail. 2007;13:

36 Potential Iatrogenic Problems Iatrogenic problems to avoid: Arrhythmias due to: Electrolyte abnormalities Stopping beta-blocker Starting new medications without appropriate follow-up Amiodarone Aldosterone antagonist Worsened renal function Not as easy to avoid as it sounds Should we accept some worsening of renal function? Nesiritide? Adenosine antagonists? Ultrafiltration? Answer: No, no, and no.

37 Admission 2 76 y.o. woman with HTN is taken to the ER from her 4 th of July BBQ because of sudden SOB PE: Wt 75 kg (baseline 74 kg) BP 185/110, HR 105, SaO2 85% RA, diffuse rales, trace edema. Baseline meds: ASA 325 mg qd, HCTZ 25 mg qd, amlodipine 10 mg qd, lisinopril 20 mg qd CXR: Normal cardiac silhouette, diffuse pulmonary edema ECG: Sinus tachycardia at 105 bpm, LVH with repolarization abnormality

38 Admission 2 Labs: Na 137, K 4.1, Cr 1.6 (baseline 1.6), BNP 450, troponin I <0.1. ABG: 7.49/28/50 on RA Baseline echo: Normal LV size/systolic function, moderate LVH, 2+ MR

39 What Do You Do? What should you do immediately? 1) Intubation, furosemide 2) BIPAP, sublingual nitroglycerin, furosemide 3) BIPAP, nitroglycerin drip, furosemide 4) BIPAP, dobutamine, furosemide

40 What Do You Do? What should you do immediately? 1) Intubation, furosemide 2) BIPAP, sublingual nitroglycerin, furosemide 3) BIPAP, nitroglycerin drip, furosemide 4) BIPAP, dobutamine, furosemide

41 What is the Problem? Characteristic findings in a patient who develops flash pulmonary edema: Poorly compliant ventricle (often with LVH) Can be worsened by ischemia Small weight gain, relatively unimpressive BNP Often have significant mitral regurgitation Almost always hypertensive at presentation

42 What is the Solution? In this patient, the main problem is increased pressure afterload or preload in noncompliant ventricle LVEDP wedge pressure (especially with MR) pulmonary edema afterload

43 What is the Solution? Patient is in a vicious cycle Pulmonary edema/hypoxia distress/raised BP worsened pulmonary edema/hypoxia Pulmonary edema/hypoxia ischemia worsened pulmonary edema/hypoxia Time is of the essence you are at a crossroads Quick, decisive action rapid improvement Delayed (or unaggressive) action worsening of vicious cycle

44 How to Treat this Patient Vasodilator at reasonable doses Nitroglycerin (can start with SL) Nitroprusside Nesiritide Diuresis Important, but not as important Respiratory support Oxygen BIPAP (also helps lower preload) Intubation beware sudden hypotension!

45 What to Tell this Patient Long Term This is the patient most sensitive to sodium intake Literally one indiscretion flash pulmonary edema Focus on BP control Role of conventional heart failure medications not clear No indication for device therapy (e.g. ICD, resynchronization)

46 Patient 3 45 y.o. man with idiopathic dilated cardiomyopathy ER for nausea/vomiting, abdominal pain Exam: Vitals: AF BP 80/40 HR 120 RR 22 SaO2 95% RA + scleral icterus/mild jaundice JVP elevated to 20 cm H 2 O Loud S3 gallop Abd: Distended, diffusely tender but worst over RUQ, equivocal Murphy s sign Ext: Clammy, 2+ bilateral edema

47 Patient 3 CXR: Cardiomegaly, mild interstitial thickening, no obvious pulmonary edema Baseline echo: Severe LV dilatation, LVEF 20%, 3+ MR, 2-3+ TR, RVSP = 55 mmhg

48 Patient 3 Outpatient meds: Carvedilol mg bid, lisinopril 2.5 mg bid, furosemide 80 mg bid, digoxin mg qd, spironolactone 25 mg qd Labs: Na 128, K 5.6, Cr 2.0 (baseline 1.4) Bilirubin 5.4 (baseline 1.0), Alk phos 180, INR 1.5, AST 240, ALT 300, WBC 10k, BNP 2500, Lipase 60

49 ECG: Sinus tach at 120, nonspecific ST-T changes (unchanged from baseline except HR) Patient 3 STAT RUQ U/S: + gallbladder wall thickening possibly c/w cholecystitis, + ascites, normal CBD

50 What Do You Do? 1) Consult surgery for cholecystectomy 2) Start on Abx/fluids for cholecystitis 3) Diurese 4) Diurese/afterload reduce 5) Diurese/pressors 6) Diurese/inotropes

51 What Do You Do? 1) Consult surgery for cholecystectomy 2) Start on Abx/fluids for cholecystitis 3) Diurese 4) Diurese/afterload reduce 5) Diurese/pressors 6) Diurese/inotropes

52 What is the Diagnosis? Low output heart failure (e.g. cardiogenic shock) Keys to the diagnosis: Hypotension, elevated JVP, S3 Frequently present differently than you might think GI complaints Elevated LFTs (can be bili or transaminase pattern) Worsened renal function Much less common: Pulmonary edema/hypoxia

53 How to Functionally Manage This Patient Augment forward flow Afterload reduce if possible (cannot now due to hypotension) Inotrope (different from pressor!) Diurese Mechanical support IABP LVAD Transplant? Remember to look for an inciting cause!

54 Inotropes vs. Pressors These agents do three basic things: Vasodilate Vasoconstrict ( pressor ) Inotropy What agent to choose = what are you trying to achieve? Septic patient: Problem is inappropriate vasodilatation use vasoconstrictor Hypertensive pulmonary edema (patient 2): Problem is inappropriate vasoconstriction use vasodilator Cardiogenic shock patient: Problem is weak muscle/low cardiac output use inotropic agent + vasodilator (as tolerated)

55 What Do the Drugs Do? -1: Vasoconstrict -1: Inotropy (& chronotropy) -2: Vasodilate NO: Vasodilate Natriuretic peptide: Vasodilate Vasopressin: Vasoconstrict ( vaso pressin ) Phosphodiesterase Inhibitor: Inotrope/vasodilator

56 Pressors: What Do the Drugs Do? Pure: Phenylephrine, Vasopressin Mixed: Norepinephrine, Epinephrine, Ephedrine Vasodilators: Nitroglycerin, Nitroprusside, Nesiritide (BNP) Inotropes/vasodilators: Dobutamine, Milrinone Inotropes/vasodilator/vasoconstrictor: Dopamine

57 IV Drips From Vasodilators to Pressors NTG/Nitroprusside/Nesiritide Vasodilatation Dobutamine/Milrinone Dopamine Epinephrine Norepinephrine Inotropy Phenylephrine/Vasopressin Vasoconstriction

58 A Word on Dopamine Used frequently in CCU/ICU setting Familiarity with it Some inotropy, some BP support /no hypotension Hits dopamine, -1, 1 receptors Lowest doses: Predominantly dopamine receptor Smaller doses: Dopamine/beta receptors Middle-higher doses: All receptors Remember: None of this is pure! Dopamine vs. Dobutamine Do you want some vasoconstrictive action or not?

59 Finally A Word on BNP Monitoring BNP s use: Distinguishing HF vs. non-hf cause of acute dyspnea Should we be measuring regular BNPs & guiding therapy by it? General answer: NO! Biggest trial: TIME-CHF trial 499 patients age >60 with NYHA II-IV HF All with HF hospitalization within past year Intervention: Symptom-guided management or NT-BNP-guided therapy Primary endpoints: 18-month survival free of hospitalization & QOL at 18 months Not blinded to physician only patient (possible bias)

60 No Difference in Hospital-Free Surivival Adapted from Pfisterer et al. JAMA 2009;301:

61 No Difference in QOL (If Anything Better Without NT-BNP!) Minnesota Living with Heart Failure Score Adapted from Pfisterer et al. JAMA 2009;301:

62 Summary Avoid term heart failure exacerbation 3 patients, 3 problems, 3 treatments Patient 1 Volume overload: Diurese Patient 2 Pressure overload: Vasodilate Patient 3 Low output: Inotropic/mechanical support Other key points to remember What caused the admission? Salt restriction is key; water restriction isn t Avoid stopping beta-blocker (except #3) Remember drug-interactions Short-term f/u in clinic & electrolyte f/u

63 ? Slides on NE vs. DA controversy & DOSE trial

64 Thank you!

Cardiology Pearls for the Hospitalist. Ronald Witteles, M.D. Stanford University School of Medicine November 2, 2013

Cardiology Pearls for the Hospitalist. Ronald Witteles, M.D. Stanford University School of Medicine November 2, 2013 Cardiology Pearls for the Hospitalist Ronald Witteles, M.D. Stanford University School of Medicine November 2, 2013 I have nothing to disclose Disclosures Outline Five cases you will encounter Diagnostic

More information

Disclosures. Heart Failure Pearls for the Hospitalist. Outline. Patient 1

Disclosures. Heart Failure Pearls for the Hospitalist. Outline. Patient 1 I have nothing to disclose Disclosures Heart Failure Pearls for the Hospitalist Ronald Witteles, M.D. Stanford University School of Medicine October 21, 2017 @Ron_Witteles Outline n Admission for Heart

More information

CASE STUDIES IN ADVANCED HEART FAILURE

CASE STUDIES IN ADVANCED HEART FAILURE CASE STUDIES IN ADVANCED HEART FAILURE Navin Rajagopalan, MD Director, Congestive Heart Failure Medical Director, Cardiac Transplantation Gill Heart Institute, Cardiovascular Medicine DISCLOSURES NOTHING

More information

Protocol Identifier Subject Identifier Visit Description. [Y] Yes [N] No. [Y] Yes [N] N. If Yes, admission date and time: Day Month Year

Protocol Identifier Subject Identifier Visit Description. [Y] Yes [N] No. [Y] Yes [N] N. If Yes, admission date and time: Day Month Year PAST MEDICAL HISTORY Has the subject had a prior episode of heart failure? o Does the subject have a prior history of exposure to cardiotoxins, such as anthracyclines? URGENT HEART FAILURE VISIT Did heart

More information

Management of acute decompensated heart failure and cardiogenic shock. Arintaya Phrommintikul Department of Medicine CMU

Management of acute decompensated heart failure and cardiogenic shock. Arintaya Phrommintikul Department of Medicine CMU Management of acute decompensated heart failure and cardiogenic shock Arintaya Phrommintikul Department of Medicine CMU Acute heart failure: spectrum Case 64 y/o M with Hx of non-ischemic DCM (LVEF=25-30%)

More information

Heart Failure. Jay Shavadia

Heart Failure. Jay Shavadia Heart Failure Jay Shavadia Definition Clinical syndrome characterized by: Symptoms: breathlessness at rest or on exercise, fatigue, tiredness or ankle swelling AND Signs: tachycardia, tachypnea, pulmonary

More information

Medical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011

Medical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011 Medical Treatment for acute Decompensated Heart Failure Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011 2010 HFSA guidelines for ADHF 2009 focused update of the 2005 American College

More information

Tips & tricks on how to treat an acute heart failure patient with low cardiac output and diuretic resistance

Tips & tricks on how to treat an acute heart failure patient with low cardiac output and diuretic resistance Tips & tricks on how to treat an acute heart failure patient with low cardiac output and diuretic resistance J. Parissis Attikon University Hospital, Athens, Greece Disclosures ALARM investigator received

More information

MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION

MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION FRANCIS X. CELIS, D.O. OPSO FALL CONFERENCE PORTLAND, OR 16 SEPTEMBER 2017 OVERVIEW What are the ACC/AHA Stages of HF? What

More information

Medical Management of Acutely Decompensated Heart Failure. William T. Abraham, MD Director, Division of Cardiovascular Medicine

Medical Management of Acutely Decompensated Heart Failure. William T. Abraham, MD Director, Division of Cardiovascular Medicine Medical Management of Acutely Decompensated Heart Failure William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Goals of Acute Heart Failure Therapy Alleviate

More information

HEART FAILURE. Heart Failure in the US. Heart Failure (HF) 3/2/2014

HEART FAILURE. Heart Failure in the US. Heart Failure (HF) 3/2/2014 HEART FAILURE Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center March 2014 Heart Failure in the US Prevalence - ~5 million 650,000 new cases annually 300,000 deaths annually Leading

More information

State-of-the-Art Management of Chronic Systolic Heart Failure

State-of-the-Art Management of Chronic Systolic Heart Failure State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures

More information

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions.

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions. Heart Failure Heart Failure Introduction and History AHA 2015 Statistics About 6 million Americans 870,000 new cases each year 1 in 9 deaths related to HF Almost 1 million hospitalizations each year (cost

More information

Diagnosis & Management of Heart Failure. Abena A. Osei-Wusu, M.D. Medical Fiesta

Diagnosis & Management of Heart Failure. Abena A. Osei-Wusu, M.D. Medical Fiesta Diagnosis & Management of Heart Failure Abena A. Osei-Wusu, M.D. Medical Fiesta Learning Objectives: 1) Become familiar with pathogenesis of congestive heart failure. 2) Discuss clinical manifestations

More information

Heart Failure. Dr. William Vosik. January, 2012

Heart Failure. Dr. William Vosik. January, 2012 Heart Failure Dr. William Vosik January, 2012 Questions for clinicians to ask Is this heart failure? What is the underlying cause? What are the associated disease processes? Which evidence-based treatment

More information

Acute heart failure, beyond conventional treatment: persisting low output

Acute heart failure, beyond conventional treatment: persisting low output Acute heart failure, beyond conventional treatment: persisting low output Alexandre Mebazaa, FESC Hôpital Lariboisière, Université Paris 7 U942 Inserm Conflict of Interest Lecture fee: Orion No other conflicts

More information

Medical Management of Acute Heart Failure

Medical Management of Acute Heart Failure Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training

More information

ACUTE HEART FAILURE. Julie Gorchynski MD, MSc, FACEP, FAAEM. Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014

ACUTE HEART FAILURE. Julie Gorchynski MD, MSc, FACEP, FAAEM. Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014 ACUTE HEART FAILURE Julie Gorchynski MD, MSc, FACEP, FAAEM Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014 No disclosures Objectives Overview Cases Current Therapy

More information

8:30-10:30 WS #4: Cardiology :00-13:00 WS #11: Cardiology 101 (Repeated)

8:30-10:30 WS #4: Cardiology :00-13:00 WS #11: Cardiology 101 (Repeated) Professor Ralph Stewart Cardiologist Auckland City Hospital Green Lane Cardiovascular Research Unit Auckland Heart Group Fiona Stewart Cardiologist Green Lane Hospital National Women's Hospital Professor

More information

Heart Failure: Guideline-Directed Management and Therapy

Heart Failure: Guideline-Directed Management and Therapy Heart Failure: Guideline-Directed Management and Therapy Guideline-Directed Management and Therapy (GDMT) was developed by the American College of Cardiology and American Heart Association to define the

More information

Nora Goldschlager, M.D. SFGH Division of Cardiology UCSF

Nora Goldschlager, M.D. SFGH Division of Cardiology UCSF CLASSIFICATION OF HEART FAILURE Nora Goldschlager, M.D. SFGH Division of Cardiology UCSF DISCLOSURES: NONE CLASSIFICATION C OF HEART FAILURE NYHA I IV New paradigm Stage A: Pts at high risk of developing

More information

Heart Failure 101 The Basic Principles of Diagnosis & Management

Heart Failure 101 The Basic Principles of Diagnosis & Management Heart Failure 101 The Basic Principles of Diagnosis & Management Bill Tran, MD Non Invasive Cardiologist February 24, 2018 What the eye does not see and the mind does not know, does not exist. DH Lawrence

More information

2016 Update to Heart Failure Clinical Practice Guidelines

2016 Update to Heart Failure Clinical Practice Guidelines 2016 Update to Heart Failure Clinical Practice Guidelines Mitchell T. Saltzberg, MD, FACC, FAHA, FHFSA Medical Director of Advanced Heart Failure Froedtert & Medical College of Wisconsin Stages, Phenotypes

More information

A patient with decompensated HF

A patient with decompensated HF A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,

More information

Evaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF<40%

Evaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF<40% Evaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF

More information

Congestive Heart Failure: Outpatient Management

Congestive Heart Failure: Outpatient Management The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy

More information

Management Strategies for Advanced Heart Failure

Management Strategies for Advanced Heart Failure Management Strategies for Advanced Heart Failure Mary Norine Walsh, MD, FACC Medical Director, HF and Cardiac Transplantation St Vincent Heart Indianapolis, IN USA President American College of Cardiology

More information

Pre-discussion questions

Pre-discussion questions Amanda Bartlett, PA-C Dustin Bartlett, PA-C Andrea Applegate, PA-C Leslie Yearta Brown, NP CHF Round Table Discussion Objectives ANDREA- Discuss the definition and different categories of CHF DUSTIN- Define

More information

HEART FAILURE. Ali Mehr, MD, FACC

HEART FAILURE. Ali Mehr, MD, FACC HEART FAILURE Ali Mehr, MD, FACC Advanced Heart Failure and Transplant Cardiologist Director, Echocardiography Lab Phoenix VA Health Care System Associate Professor of Medicine University of Arizona, COM,

More information

DIAGNOSIS AND MANAGEMENT OF ACUTE HEART FAILURE

DIAGNOSIS AND MANAGEMENT OF ACUTE HEART FAILURE DIAGNOSIS AND MANAGEMENT OF ACUTE HEART FAILURE Mefri Yanni, MD Bagian Kardiologi dan Kedokteran Vaskular RS.DR.M.Djamil Padang The 3rd Symcard Padang, Mei 2013 Outline Diagnosis Diagnosis Treatment options

More information

HEART FAILURE. Heart Failure in the US. Heart Failure (HF) 10/5/2015. Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center

HEART FAILURE. Heart Failure in the US. Heart Failure (HF) 10/5/2015. Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center HEART FAILURE Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center Heart Failure in the US Prevalence - ~5 million 650,000 new cases annually 300,000 deaths annually Leading DRG among

More information

Heart Failure Symposium: Case Presentation (The crash and burn and the smoldering patient)

Heart Failure Symposium: Case Presentation (The crash and burn and the smoldering patient) Heart Failure Symposium: (The crash and burn and the smoldering patient) Patrick C. Magnus, MBBS, MPH Clinical Fellow Section of Cardiology Dartmouth Hitchcock Medical Center (Case 1) 66 year old man,

More information

Rounds in the ICU. Eran Segal, MD Director General ICU Sheba Medical Center

Rounds in the ICU. Eran Segal, MD Director General ICU Sheba Medical Center Rounds in the ICU Eran Segal, MD Director General ICU Sheba Medical Center Real Clinical cases (including our mistakes) Emphasis on hemodynamic monitoring Usually no single correct answer We will conduct

More information

Definition of Congestive Heart Failure

Definition of Congestive Heart Failure Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million

More information

Introduction. Invasive Hemodynamic Monitoring. Determinants of Cardiovascular Function. Cardiovascular System. Hemodynamic Monitoring

Introduction. Invasive Hemodynamic Monitoring. Determinants of Cardiovascular Function. Cardiovascular System. Hemodynamic Monitoring Introduction Invasive Hemodynamic Monitoring Audis Bethea, Pharm.D. Assistant Professor Therapeutics IV January 21, 2004 Hemodynamic monitoring is necessary to assess and manage shock Information obtained

More information

Cardiorenal and Renocardiac Syndrome

Cardiorenal and Renocardiac Syndrome And Renocardiac Syndrome A Vicious Cycle Cardiorenal and Renocardiac Syndrome Type 1 (acute) Acute HF results in acute kidney injury Type 2 Chronic cardiac dysfunction (eg, chronic HF) causes progressive

More information

CLASIFICATION OF ACUTE HEART FAILURE

CLASIFICATION OF ACUTE HEART FAILURE CLASIFICATION OF ACUTE HEART FAILURE CLINICAL STATUS HR SBP mmhg CI L/min/m 2 PCWP mmhg Congestion Killip/Forrester Diuresis Hupoperfusion End-organ hypoperfusion I. Acute decompensated CHF +/ Low normal

More information

Updates in Heart Failure - Rx

Updates in Heart Failure - Rx Updates in Heart Failure - Rx Pragnesh Parikh, M.D. Mayo Clinic Florida 2015 MFMER slide-1 Disclosures None. 2015 MFMER slide-2 Overview Epidemiology of ADHF Goals of acute management Pharmacologic Management:

More information

Intravenous Inotropic Support an Overview

Intravenous Inotropic Support an Overview Intravenous Inotropic Support an Overview Shaul Atar, MD Western Galilee Medical Center, Nahariya Affiliated with the Faculty of Medicine of the Galilee, Safed, Israel INOTROPES in Acute HF (not vasopressors)

More information

Heart Failure Teri Diederich, APRN April 7, Objectives. Heart Failure Statistics 3/29/2016

Heart Failure Teri Diederich, APRN April 7, Objectives. Heart Failure Statistics 3/29/2016 Heart Failure Teri Diederich, APRN April 7, 2016 Objectives Verbalize heart failure statistics Understand cardiac anatomy and physiology Define heart failure and it s effects on cardiac anatomy Identify

More information

5 Important Things to Know About Heart Failure. Kia Afshar, MD

5 Important Things to Know About Heart Failure. Kia Afshar, MD 5 Important Things to Know About Heart Failure Kia Afshar, MD Disclosures I have no conflicts of interest to disclose I will not be discussing any off label medications and/or devices Objectives 1) Understand

More information

Heart Failure Dr ahmed almutairi Assistant professor internal medicin dept

Heart Failure Dr ahmed almutairi Assistant professor internal medicin dept Heart Failure Dr ahmed almutairi Assistant professor internal medicin dept (MBBS)(SBMD) Introduction Epidemiology Pathophysiology diastolic/systolic Risk factors Signs and symptoms Classification of HF

More information

Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation

Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation Objectives Current rationale behind use of MCS Patient Selection Earlier?

More information

CHF ICU to community. Disclosure slide CHF. Diagnosis. Diagnosis. Diagnostic modalties Therapeutic modalities. Talks. Advisory boards.

CHF ICU to community. Disclosure slide CHF. Diagnosis. Diagnosis. Diagnostic modalties Therapeutic modalities. Talks. Advisory boards. CHF ICU to community CHF Diagnostic modalties Therapeutic modalities ICU Pacer/ ICD Medication CHF clinic ASV - Nejm. Sept. 17,2015. Advanced care directives Disclosure slide Talks most companies Advisory

More information

Nothing to Disclose. Severe Pulmonary Hypertension

Nothing to Disclose. Severe Pulmonary Hypertension Severe Ronald Pearl, MD, PhD Professor and Chair Department of Anesthesiology Stanford University Rpearl@stanford.edu Nothing to Disclose 65 year old female Elective knee surgery NYHA Class 3 Aortic stenosis

More information

Is it HF secondary to rheumatic heart disease???

Is it HF secondary to rheumatic heart disease??? Is it HF secondary to rheumatic heart disease??? Is mitral regurg. Is complication of CHF??? Cardiomyopathy Definition The term cardiomyopathy is purely descriptive, meaning disease of the heart muscle

More information

Case Summary. Workshop Overview. Mr. M

Case Summary. Workshop Overview. Mr. M 9:00 10:30 Workshop Overview Mr. M Who is this document primarily intended to reach? What is the format? How soon should I see a newly referred heart failure patient? How often should my heart failure

More information

Congestive Heart Failure Patient Profile. Patient Identity - Mr. Douglas - 72 year old man - No drugs, smokes, moderate social alcohol consumption

Congestive Heart Failure Patient Profile. Patient Identity - Mr. Douglas - 72 year old man - No drugs, smokes, moderate social alcohol consumption Congestive Heart Failure Patient Profile Patient Identity - Mr. Douglas - 72 year old man - No drugs, smokes, moderate social alcohol consumption Chief Complaint - SOB - When asked: Increasing difficulty

More information

เอกราช อร ยะช ยพาณ ชย

เอกราช อร ยะช ยพาณ ชย 25 September 2017 เอกราช อร ยะช ยพาณ ชย Heart Failure and Transplant Cardiology aekarach.a@chula.ac.th Presentation at 1 Agenda Physiology of the heart Pathophysiology of shock Pathophysiology of heart

More information

Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes?

Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes? Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor

More information

Estimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches

Estimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches Heart Failure: Management of a Chronic Disease Jenny Bauerly RN, CHFN, APRN-BC Heart Failure (HF) Definition A complex clinical syndrome that can result from any structural or functional cardiac disorder

More information

Heart Failure CTSHP Fall Seminar

Heart Failure CTSHP Fall Seminar Heart Failure CTSHP Fall Seminar Laurajo Ryan, PharmD, MSc, BCPS, CDE Pharmacist Learning Objectives Outline the pathophysiology of heart failure List triggers for decompensated heart failure Describe

More information

Heart Failure Clinician Guide JANUARY 2018

Heart Failure Clinician Guide JANUARY 2018 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.

More information

Agenda เอกราช อร ยะช ยพาณ ชย. - Cardiac physiology - Pathophysiology of shock - Pathophysiology of heart failure 9/6/2016

Agenda เอกราช อร ยะช ยพาณ ชย. - Cardiac physiology - Pathophysiology of shock - Pathophysiology of heart failure 9/6/2016 6 September 2016 เอกราช อร ยะช ยพาณ ชย Heart Failure and Transplant Cardiology aekarach.a@chula.ac.th Agenda - Cardiac physiology - Pathophysiology of shock - Pathophysiology of heart failure http://fullpulse.weebly.com/conversation

More information

Optimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists

Optimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists Optimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists Old Drugs for an Old Problem Jay Geoghagan, MD, FACC BHHI Primary Care Symposium February 28, 2014 None. Financial disclosures

More information

DISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE

DISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION Lori M. Tam, MD Providence Heart Institute DISCLOSURES NONE 1 OUTLINE Systolic vs. Diastolic Heart Failure New

More information

Heart Failure Treatments

Heart Failure Treatments Heart Failure Treatments Past & Present www.philippelefevre.com Background Background Chronic heart failure Drugs Mechanical Electrical Background Chronic heart failure Drugs Mechanical Electrical Sudden

More information

HEART FAILURE. Heart Failure in the US. Heart Failure (HF) 2/20/2017. Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center

HEART FAILURE. Heart Failure in the US. Heart Failure (HF) 2/20/2017. Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center HEART FAILURE Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center Heart Failure in the US Prevalence - ~5 million 650,000 new cases annually 300,000 deaths annually Leading DRG among

More information

HEART FAILURE: PHARMACOTHERAPY UPDATE

HEART FAILURE: PHARMACOTHERAPY UPDATE HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis

More information

Heart Failure Clinician Guide JANUARY 2016

Heart Failure Clinician Guide JANUARY 2016 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.

More information

Impedance Cardiography (ICG) Application of ICG in Intensive Care and Emergency

Impedance Cardiography (ICG) Application of ICG in Intensive Care and Emergency Impedance Cardiography (ICG) Application of ICG in Intensive Care and Emergency Aim of haemodynamic monitoring in ICU and ED Detection and therapy of insufficient organ perfusion Answers to common cardiovascular

More information

Question by Question (QXQ) Instructions for the HCHS/SOL Heart Failure Diagnosis Form (HFD)

Question by Question (QXQ) Instructions for the HCHS/SOL Heart Failure Diagnosis Form (HFD) Question by Question (QXQ) Instructions for the HCHS/SOL Heart Failure Diagnosis Form (HFD) A Heart Failure Diagnosis (HFD) Form is filled out by the reviewer for all case packets that are sent to them

More information

Advanced Heart Failure Management. Dr Andrew Hannah Consultant Cardiologist Aberdeen Royal Infirmary

Advanced Heart Failure Management. Dr Andrew Hannah Consultant Cardiologist Aberdeen Royal Infirmary Advanced Heart Failure Management Dr Andrew Hannah Consultant Cardiologist Aberdeen Royal Infirmary Grading of heart failure Mr WY age 73 3/12 dyspnoea, fatigue and some ankle oedema PMH: hypertension

More information

WHAT IS ADVANCED HEART FAILURE? James C. Fang, MD, FACC Professor and Chief Cardiovascular Division University of Utah School of Medicine

WHAT IS ADVANCED HEART FAILURE? James C. Fang, MD, FACC Professor and Chief Cardiovascular Division University of Utah School of Medicine WHAT IS ADVANCED HEART FAILURE? James C. Fang, MD, FACC Professor and Chief Cardiovascular Division University of Utah School of Medicine Disclosures Data Safety Monitoring Board SOPRANO (J&J), EVALUATE-HF

More information

Pivotal Role of Renal Function in Acute Heart failure

Pivotal Role of Renal Function in Acute Heart failure Pivotal Role of Renal Function in Acute Heart failure Doron Aronson MD, FESC Department of Cardiology RAMBAM Health Care Campus Haifa, Israel Classification and definitions of cardiorenal syndromes CRS

More information

Pulmonary Hypertension: Another Use for Viagra

Pulmonary Hypertension: Another Use for Viagra Pulmonary Hypertension: Another Use for Viagra Kathleen Tong, MD Director, Heart Failure Program Assistant Clinical Professor University of California, Davis Disclosures I have no financial conflicts A

More information

Swans and Pressors. Vanderbilt Surgery Summer School Ricky Shinall

Swans and Pressors. Vanderbilt Surgery Summer School Ricky Shinall Swans and Pressors Vanderbilt Surgery Summer School Ricky Shinall Shock, Swans, Pressors in 15 minutes 4 Reasons for Shock 4 Swan numbers to know 7 Pressors =15 things to know 4 Reasons for Shock Not enough

More information

FAILURE. Matt Beecroft, MD

FAILURE. Matt Beecroft, MD FAILURE Matt Beecroft, MD 64 yo male with no real PMH Sitting on couch when sudden onset SOB Says he s been sweaty FIRST PATIENT OF THE WEEKEND HR 131, RR 28, 132/96, 93% RE-EXAM BP 229/130, HR 180s

More information

What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine

What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine Current Guideline of Treatment Asymptomatic Mild/Mod Severe Refractory Correct Cause: Arrhythmias

More information

Summary/Key Points Introduction

Summary/Key Points Introduction Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification

More information

Using Lung Ultrasound to Diagnose and Manage Acute Heart Failure

Using Lung Ultrasound to Diagnose and Manage Acute Heart Failure Using Lung Ultrasound to Diagnose and Manage Acute Heart Failure Jennifer Martindale, MD Assistant Professor Department of Emergency Medicine SUNY Downstate/Kings County Hospital Brooklyn, NY What is acute

More information

Vasoactive Medications. Matthew J. Korobey Pharm.D., BCCCP Critical Care Clinical Specialist Mercy St. Louis

Vasoactive Medications. Matthew J. Korobey Pharm.D., BCCCP Critical Care Clinical Specialist Mercy St. Louis Vasoactive Medications Matthew J. Korobey Pharm.D., BCCCP Critical Care Clinical Specialist Mercy St. Louis Objectives List components of physiology involved in blood pressure Review terminology related

More information

Heart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)

Heart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea) Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types

More information

The Failing Heart in Primary Care

The Failing Heart in Primary Care The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and

More information

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G. Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center

More information

Integrating Current Knowledge into Consensus Guidelines for Acute Decompensated Heart Failure

Integrating Current Knowledge into Consensus Guidelines for Acute Decompensated Heart Failure Integrating Current Knowledge into Consensus Guidelines for Acute Decompensated Heart Failure J. Herbert Patterson, Pharm.D., FCCP One of Four Continuing Education Programs in the Series, Acute Decompensated

More information

Gina G. Mentzer, MD Cardiologist, Heart Failure & Transplant Advanced Integrated Medicine & Surgery (AIMS) Program for Heart Failure April 18 th,

Gina G. Mentzer, MD Cardiologist, Heart Failure & Transplant Advanced Integrated Medicine & Surgery (AIMS) Program for Heart Failure April 18 th, Gina G. Mentzer, MD Cardiologist, Heart Failure & Transplant Advanced Integrated Medicine & Surgery (AIMS) Program for Heart Failure April 18 th, 2015 Heart Failure (HF) Describe the natural course of

More information

Swans and Pressors. Vanderbilt Surgery Summer School Ricky Shinall

Swans and Pressors. Vanderbilt Surgery Summer School Ricky Shinall Swans and Pressors Vanderbilt Surgery Summer School Ricky Shinall SHOCK Hypotension SHOCK Hypotension SHOCK=Reduction of systemic tissue perfusion, resulting in decreased oxygen delivery to the tissues.

More information

Peripartum Cardiomyopathy. Lavanya Rai Manipal

Peripartum Cardiomyopathy. Lavanya Rai Manipal Peripartum Cardiomyopathy Lavanya Rai Manipal Definition - PPCM - Dilated cardiomyopathy of unknown cause resulting in cardiac failure that occurs in the peripartum period in women without any preexisting

More information

Heart Failure Update. Bibiana Cujec MD May 2015

Heart Failure Update. Bibiana Cujec MD May 2015 Heart Failure Update Bibiana Cujec MD May 2015 Disclosures Participation in clinical trial GUIDE IT (BNP in management of HF) Plan Review of new trials/ccs guidelines Management of heart failure: cases

More information

Copyright 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Normal Cardiac Anatomy

Copyright 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Normal Cardiac Anatomy Mosby,, an affiliate of Elsevier Normal Cardiac Anatomy Impaired cardiac pumping Results in vasoconstriction & fluid retention Characterized by ventricular dysfunction, reduced exercise tolerance, diminished

More information

2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much?

2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much? 2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much? Dr. Shelley Zieroth University of Manitoba @ShelleyZieroth @CanHFSociety Disclosures Consulting/Advisory Board: Amgen, Astra

More information

Case 1. Case 2. What do you think about reducing or discontinuing some of the above now that his LVEF has normalized?

Case 1. Case 2. What do you think about reducing or discontinuing some of the above now that his LVEF has normalized? Case 1 A primary care colleague inquires what to do with a patient (HFrEF in NSR) who has a digoxin level of 2.8ng/ml. Level was obtained at 10am, patient takes all medications at one time upon arising

More information

Incidence. 4.8 million in the United States. 400,000 new cases/year. 20 million patients with asymptomatic LV dysfunction

Incidence. 4.8 million in the United States. 400,000 new cases/year. 20 million patients with asymptomatic LV dysfunction Heart Failure Diagnosis According to the Working Group in Heart Failure, CHF is a syndrome where the diagnosis has the following essential components: A combination of: Symptoms, typically breathlessness

More information

From PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group

From PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF

More information

Updates in Diagnosis & Management of CHF

Updates in Diagnosis & Management of CHF Updates in Diagnosis & Management of CHF N. Goldberg, DO April 30, 2011 CHF CHF is reaching an epidemic level in U.S. and continues to worsen over time Reasons are: HTN Dm with sedentary lifestyle and

More information

DAY1_CARDIOVASCULAR PRACTICE QUESTIONS

DAY1_CARDIOVASCULAR PRACTICE QUESTIONS DAY1_CARDIOVASCULAR PRACTICE QUESTIONS 1 P age 1. A 59-year-old male is admitted complaining of chest pain and dyspnea. ST elevation and T-wave inversion were seen on the ECG in V2, V3, and V4. IV thrombolytic

More information

Introduction to Heart Failure. Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL

Introduction to Heart Failure. Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL Introduction to Heart Failure Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL Disclosures No relevant financial relationships to disclose Objectives and Outline Define heart

More information

Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides

Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Colette Seifer MB(Hons) FRCP(UK) Associate Professor, University of Manitoba, Cardiologist, Cardiac Sciences Program, St Boniface Hospital

More information

Heart Failure. Dr. Alia Shatanawi

Heart Failure. Dr. Alia Shatanawi Heart Failure Dr. Alia Shatanawi Left systolic dysfunction secondary to coronary artery disease is the most common cause, account to 70% of all cases. Heart Failure Heart is unable to pump sufficient blood

More information

Heart Failure A Disease for the Internist?

Heart Failure A Disease for the Internist? Heart Failure A Disease for the Internist? Dr Chris Davidson Sussex Cardiac Centre BRIGHTON UK Hot Topics in Heart Failure Drug treatments Valsartan / neprilysin inhib Investigations BNP and others Devices

More information

HEART FAILURE. Study day November 2018 Sarah Briggs

HEART FAILURE. Study day November 2018 Sarah Briggs HEART FAILURE Study day November 2018 Sarah Briggs Overview and Introduction This course is an introduction and overview of heart failure. Normal heart function and basic pathophysiology of heart failure

More information

ICD Guidelines: who benefits from an ICD?

ICD Guidelines: who benefits from an ICD? ICD Guidelines: who benefits from an ICD? Matthew Bennett Cardiac Electrophysiologist Vancouver Coastal Health, Device Lead Associate Professor, UBC Matthew.bennett@vch.ca Disclosures I have research collaborations

More information

Difficult Data Definitions and Scenario s

Difficult Data Definitions and Scenario s Difficult Data Definitions and Scenario s Presenter Disclosure Information Cornelia Anderson BSN, RN To following relationships exist related to this presentation: No Disclosures Objectives Discuss key

More information

Heart Failure (HF) Treatment

Heart Failure (HF) Treatment Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and

More information

Update in Congestive Hear Failure DRAGOS VESBIANU MD

Update in Congestive Hear Failure DRAGOS VESBIANU MD Update in Congestive Hear Failure DRAGOS VESBIANU MD Case 58 yo AAM c/o shortness of breath for 3 weeks. Used to walk one mile per day and now he has noticed that he gets short of breath after 2 blocks.

More information

Valvular heart disease : Role of medication ( drug and intervention ) Pol.Col.Dr.Kasem Ratanasumawong

Valvular heart disease : Role of medication ( drug and intervention ) Pol.Col.Dr.Kasem Ratanasumawong Valvular heart disease : Role of medication ( drug and intervention ) Pol.Col.Dr.Kasem Ratanasumawong Management of valvular heart disease Accurate diagnosis and disease severity Prevention and treatment

More information

Akash Ghai MD, FACC February 27, No Disclosures

Akash Ghai MD, FACC February 27, No Disclosures Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%

More information

Clinical Case. Female, 62 years January 2016

Clinical Case. Female, 62 years January 2016 Clinical Case Female, 62 years January 2016 Dr. Ramón Corbalán H. Facultad de Medicina División de Enfermedades Cardiovasculares Pontificia Universidad Católica de Chile Clinical Hx Background: Ostheoartritis

More information

7/21/2017. Learning Objectives. Current Cardiovascular Pharmacology. Epinephrine. Cardiotonic Agents. Epinephrine. Epinephrine. Arthur Jones, EdD, RRT

7/21/2017. Learning Objectives. Current Cardiovascular Pharmacology. Epinephrine. Cardiotonic Agents. Epinephrine. Epinephrine. Arthur Jones, EdD, RRT Learning Objectives Current Cardiovascular Pharmacology Arthur Jones, EdD, RRT Explain the actions, effects, indications, adverse effects, & precautions for agents from the following drug categories Cardiotonic

More information